CHARACTERIZATION OF CISPLATIN-GLUTATHIONE ADDUCTS BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY - EVIDENCE FOR THEIR FORMATION IN-VITRO BUT NOT IN-VIVO AFTER CONCOMITANT ADMINISTRATION OF CISPLATIN AND GLUTATHIONE TO RATS AND CANCER-PATIENTS

被引:35
作者
BERNAREGGI, A
TORTI, L
FACINO, RM
CARINI, M
DEPTA, G
CASETTA, B
FARRELL, N
SPADACINI, S
CESERANI, R
TOGNELLA, S
机构
[1] UNIV MILAN,IST CHIM FARMACEUT TOSSICOL,MILAN,ITALY
[2] PERKIN ELMER ESSC,MUNICH,GERMANY
[3] VIRGINIA COMMONWEALTH UNIV,DEPT CHEM,RICHMOND,VA 23284
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1995年 / 669卷 / 02期
关键词
D O I
10.1016/0378-4347(95)00098-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
After incubation of equimolar amounts of cisplatin (CDDP) and glutathione (GSH) in phosphate buffer pH 7.4 at 37 degrees C, we detected two CDDP-GSH adducts whose structures, characterized by LC-MS, corresponded to cis-[Pt(NH3)(2)Cl(SG)] and cis-{[Pt(NH3)(2)Cl](2)(mu-SG)}(+). The latter is a new CDDP-GSH adduct, which was postulated but never structurally characterized so far. Rats and patients were given a 15-min intravenous infusion of CDDP (10 mg/kg to rats and 25 mg/m(2) to patients) preceded by a GSH intravenous administration (200 mg/kg to rats as a bolus and 1.5 g/m(2) to patients as a 15-min infusion). After the administrations, CDDP-GSH adducts were absent in rat and human plasma ultrafiltrates. The discrepancy between in vitro and in vivo findings can be explained based on pharmacokinetic considerations.
引用
收藏
页码:247 / 263
页数:17
相关论文
共 27 条
[1]   HIGH-DOSE INTRAVENOUS GLUTATHIONE IN MAN - PHARMACOKINETICS AND EFFECTS ON CYST(E)INE IN PLASMA AND URINE [J].
AEBI, S ;
ASSERETO, R ;
LAUTERBURG, BH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (01) :103-110
[2]   NMR-STUDY OF THE REACTIONS OF THE CIS-DIAMMINEDIAQUAPLATINUM(II) CATION WITH GLUTATHIONE AND AMINO-ACIDS CONTAINING A THIOL-GROUP [J].
APPLETON, TG ;
CONNOR, JW ;
HALL, JR ;
PRENZLER, PD .
INORGANIC CHEMISTRY, 1989, 28 (11) :2030-2037
[3]   REACTION OF CIS-[PTCL2[NH3]2] AND TRANS-[PTCL2(NH3)2] WITH REDUCED GLUTATHIONE INSIDE HUMAN RED-BLOOD-CELLS, STUDIED BY H-1-[H-1] AND N-15-[H-1] DEPT NMR [J].
BERNERSPRICE, SJ ;
KUCHEL, PW .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1990, 38 (04) :327-345
[4]   REACTION OF CIS-[PTCL2(NH3)2] AND TRANS-[PTCL2(NH3)2] WITH REDUCED GLUTATHIONE STUDIED BY H-1-[H-1], C-13[H-1], PT-195[H-1] AND N-15-[H-1] DEPT NMR [J].
BERNERSPRICE, SJ ;
KUCHEL, PW .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1990, 38 (04) :305-326
[5]  
CASCINU S, 1994, 30TH P ANN M AM SOC, V13, P431
[6]   CHARACTERIZATION OF THE REACTIONS OF PLATINUM ANTITUMOR AGENTS WITH BIOLOGIC AND NONBIOLOGICAL SULFUR-CONTAINING NUCLEOPHILES [J].
DEDON, PC ;
BORCH, RF .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (12) :1955-1964
[7]  
DIRE F, 1993, ANN ONCOL, V4, P55
[8]   EFFICACY AND SAFETY OF HIGH-DOSE CISPLATIN AND CYCLOPHOSPHAMIDE WITH GLUTATHIONE PROTECTION IN THE TREATMENT OF BULKY ADVANCED EPITHELIAL OVARIAN-CANCER [J].
DIRE, F ;
BOHM, S ;
ORIANA, S ;
SPATTI, GB ;
ZUNINO, F .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (05) :355-360
[9]  
HAMERS FPT, 1993, CANCER RES, V53, P544
[10]  
HUININK WWT, 1991, CURR OPIN ONCOL, V3, P930